ABEV's deterministic health score is weak with a Piotroski F-Score of 4/9, indicating marginal financial stability. The stock trades above the Graham Number of $2.24 at a current price of $2.78, suggesting modest overvaluation for a defensive stock, though below the growth-based intrinsic value of $5.9. Strong profitability metrics like a 17.73% profit margin and 26.01% operating margin are offset by declining revenue growth of -5.70% YoY and a concerning 104.3% dividend payout ratio. Analysts rate it a 'hold' with a $2.93 target, implying limited upside.